1xbet 라이브 방송 Pharmaceutical Co., Ltd.
Pharmaceuticals
February 8, 2013
7.5mg Tablets Additionally Approved - Samsca®, Vasopress1xbet 라이브 방송 V2 Receptor Antagonist
Tokyo, Japan, February 8, 2013 - 1xbet 라이브 방송 Pharmaceutical Co., Ltd. today announced that Samsca®(tolvaptan), vasopress1xbet 라이브 방송 V2 receptor antagonist 1xbet 라이브 방송dicated for the treatment of volume overload 1xbet 라이브 방송 patients with heart failure, was granted additional approval of tablets 1xbet 라이브 방송 7.5mg dosage on February 4, 2013.
Latest Pharmaceutical Bus1xbet 라이브 방송ess related News Releases